跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ICLUSIG - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ICLUSIG
Authorized
STANDARD
ICLUSIG
Takeda Pharmaceuticals U.S.A., Inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
2e9cf318bec4a7c6
Company
Takeda Pharmaceuticals U.S.A., Inc.
Type
Standard
Approval Details
Approval Id
2e9cf318bec4a7c6
Drug Approval Canada Name
ICLUSIG
Product Name
ICLUSIG
Status
Marketed
Status Date
2023-06-29
Original Market Date
2015-08-21
Din
02437333
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01EA05 PONATINIB
Atc Name
l 01 ea 05
Aig Number
0156590001
Company Name
Takeda Pharmaceuticals U.S.A., Inc.
Company Address
500 Kendall Street, Cambridge, Massachusetts, United States, 02142
Company Detail Path
/organization/takeda-pharmaceuticals-u-s-a-inc
Company Information
Pharmaceutical Company Name
Takeda Pharmaceuticals U.S.A., Inc.
Country Name
United States
Province Name
Massachusetts
City Name
Cambridge
Address
500 Kendall St
Website
http://www.takeda.com/en-us
Active Ingredients
PONATINIB (PONATINIB HYDROCHLORIDE)
15 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
2e9cf318bec4a7c6
Type
Standard
Back to Health Canada Approvals